DE60327606D1 - Mutiertes immunoglobulinbindendes protein - Google Patents

Mutiertes immunoglobulinbindendes protein

Info

Publication number
DE60327606D1
DE60327606D1 DE60327606T DE60327606T DE60327606D1 DE 60327606 D1 DE60327606 D1 DE 60327606D1 DE 60327606 T DE60327606 T DE 60327606T DE 60327606 T DE60327606 T DE 60327606T DE 60327606 D1 DE60327606 D1 DE 60327606D1
Authority
DE
Germany
Prior art keywords
protein
binding protein
immunoglobulin
mutated
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327606T
Other languages
English (en)
Inventor
Sophia Hober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytiva Sweden AB
Original Assignee
GE Healthcare Bio Sciences AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20287415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60327606(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GE Healthcare Bio Sciences AB filed Critical GE Healthcare Bio Sciences AB
Application granted granted Critical
Publication of DE60327606D1 publication Critical patent/DE60327606D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/24Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/289Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00Aspects relating to sorbent materials
    • B01J2220/40Aspects relating to the composition of sorbent or filter aid materials
    • B01J2220/44Materials comprising a mixture of organic materials
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00Aspects relating to sorbent materials
    • B01J2220/50Aspects relating to the use of sorbent or filter aid materials
    • B01J2220/52Sorbents specially adapted for preparative chromatography
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60327606T 2002-03-25 2003-03-20 Mutiertes immunoglobulinbindendes protein Expired - Lifetime DE60327606D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200943A SE0200943D0 (sv) 2002-03-25 2002-03-25 Mutant protein
PCT/SE2003/000475 WO2003080655A1 (en) 2002-03-25 2003-03-20 A mutated immunoglobulin-binding protein

Publications (1)

Publication Number Publication Date
DE60327606D1 true DE60327606D1 (de) 2009-06-25

Family

ID=20287415

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327606T Expired - Lifetime DE60327606D1 (de) 2002-03-25 2003-03-20 Mutiertes immunoglobulinbindendes protein

Country Status (13)

Country Link
US (9) US7834158B2 (de)
EP (3) EP1485407B2 (de)
JP (1) JP4391830B2 (de)
KR (4) KR101307714B1 (de)
CN (6) CN102558317A (de)
AT (1) ATE431360T1 (de)
AU (1) AU2003217119B2 (de)
CA (1) CA2479896C (de)
DE (1) DE60327606D1 (de)
DK (2) DK1972689T3 (de)
ES (3) ES2783876T3 (de)
SE (1) SE0200943D0 (de)
WO (1) WO2003080655A1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200943D0 (sv) 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
SE0301936D0 (sv) * 2003-06-30 2003-06-30 Affibody Ab New polypeptide
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
US8597908B2 (en) * 2004-07-06 2013-12-03 Kaneka Corporation Process for producing protein A-like protein with use of Brevibacillus genus bacterium
CA2586803C (en) * 2004-12-14 2012-12-11 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
DK1869071T3 (da) 2005-03-01 2011-02-28 Affibody Ab TNF-alfa-bindende polypeptid, anvendelser deraf og fremgangsmåder, der gør brug deraf
EP1992692B1 (de) * 2006-02-21 2013-01-09 Protenova Co., Ltd. Immunglobulin-affinitätsligand
JP5345539B2 (ja) 2006-09-29 2013-11-20 ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー 抗体単離のためのスタフィロコッカスアウレウス由来のドメインcを含むクロマトグラフィーリガンド
WO2008127457A2 (en) 2006-12-06 2008-10-23 Repligen Corporation Nucleic acids encoding recombinant protein a
WO2008143199A1 (ja) 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド,アフィニティークロマトグラフィー用材,及びイムノグロブリンの分離及び/又は精製方法
SG149759A1 (en) 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
GB2452301A (en) 2007-08-30 2009-03-04 Ge Healthcare Bio Sciences Ab Sterilization Method
KR101104417B1 (ko) * 2008-05-09 2012-01-16 한국생명공학연구원 단백질 g 변형체를 이용한 항체의 특이적 공유결합 커플링방법
JP2011523408A (ja) * 2008-05-15 2011-08-11 ノボ・ノルデイスク・エー/エス 抗体精製方法
JP5677943B2 (ja) * 2008-06-05 2015-02-25 アフィボディ・アーベーAffibody Ab ポリペプチド
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
EP2339339A4 (de) * 2008-09-25 2016-10-12 Jsr Corp Füllmittel für affinitätschromatographie
JP5229888B2 (ja) * 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインa変異型タンパク質及び抗体捕捉剤
CA2739352C (en) * 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
SG162687A1 (en) * 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
US20120149875A1 (en) * 2009-01-12 2012-06-14 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
EP2412809B1 (de) 2009-03-24 2017-08-09 Kaneka Corporation Protein mit immunglobulinaffinität und ligand mit affinität für immunglobulinbindung
AU2011230313B2 (en) 2010-03-24 2015-01-22 Kaneka Corporation Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
KR102006097B1 (ko) 2010-03-31 2019-07-31 제이에스알 가부시끼가이샤 친화성 크로마토그래피용 충전제
US20130052209A1 (en) * 2010-04-23 2013-02-28 Purdue Research Foundation Protein drug formulations and packages
WO2012001142A1 (en) 2010-07-02 2012-01-05 Novo Nordisk A/S Improved antibody binding affinity ligands
DK2632948T3 (en) * 2010-10-27 2017-02-27 Spiber Tech Ab SPIDER SILK FUSION PROTEIN INSTRUCTIONS FOR BINDING TO AN ORGANIC GOAL.
JP2014502272A (ja) * 2010-11-29 2014-01-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティークロマトグラフィーマトリックス
WO2012087230A1 (en) 2010-12-20 2012-06-28 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
US9187555B2 (en) 2010-12-20 2015-11-17 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
CN103403020A (zh) * 2010-12-21 2013-11-20 Jsr株式会社 蛋白a的新型耐碱变体及其在亲和色谱中的用途
WO2012086660A1 (ja) 2010-12-21 2012-06-28 Jsr株式会社 アフィニティークロマトグラフィー用担体およびイムノグロブリンを単離する方法
JPWO2012086837A1 (ja) * 2010-12-24 2014-06-05 旭化成メディカル株式会社 温度応答性プロテインaの固定化方法
WO2012099521A1 (en) 2011-01-20 2012-07-26 Applied Precision, Inc. Light-scanning systems
WO2012124145A1 (ja) 2011-03-15 2012-09-20 オムロン株式会社 演算ユニット、支援装置、支援プログラム、支援プログラムを格納した記憶媒体、および、支援装置における動作方法
JP6038774B2 (ja) 2011-03-24 2016-12-07 株式会社カネカ タンパク性物質結合性低分子化合物
EP2690108B1 (de) * 2011-03-25 2018-07-25 Kaneka Corporation Neuartiges immunoglobulinbindendes polypeptid
WO2012170446A2 (en) * 2011-06-05 2012-12-13 Apple Inc. Systems and methods for displaying notifications received from multiple applications
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US9657055B2 (en) * 2011-11-30 2017-05-23 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
WO2013147691A1 (en) * 2012-03-28 2013-10-03 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
CA2872305A1 (en) * 2012-05-02 2013-11-07 Spiber Technologies Ab Spider silk fusion protein structures incorporating immunoglobulin fragments as affinity ligands
JP6335785B2 (ja) 2012-09-03 2018-05-30 株式会社カネカ ミックスモード抗体アフィニティー分離マトリックスとそれを用いた精製方法および標的分子
EP2904393B1 (de) 2012-10-03 2018-11-28 Gyros Patent Ab Verfahren und kit zur analytbestimmung unter sauren bedingungen
CN104837536B (zh) 2012-12-14 2018-01-02 通用电气医疗集团生物工艺研发股份公司 清洁填充床层析柱的方法
CN104059133B (zh) * 2013-03-18 2019-03-15 南京金斯瑞生物科技有限公司 一类突变的具有高耐碱特性的蛋白a及其应用
CN103214563B (zh) * 2013-03-26 2015-09-30 江南大学 一种性能改进的重组金黄色葡萄球菌蛋白a亲和配基及其构建方法
WO2015005859A1 (en) 2013-07-10 2015-01-15 Ge Healthcare Bio-Sciences Ab Mutated immunoglobulin-binding polypeptides
JP6456831B2 (ja) * 2013-09-04 2019-01-23 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
EP3042954A4 (de) * 2013-09-06 2017-03-22 Kaneka Corporation Ligand mit verstärkter dissoziationskapazität für eine affinitätsdissoziationsmatrix
KR20160054597A (ko) 2013-09-17 2016-05-16 가부시키가이샤 가네카 신규 항체 정제 방법 및 그로부터 얻어지는 항체, 및 양이온 교환기를 사용한 신규 항체 정제법 및 그로부터 얻어지는 항체
CN103540588B (zh) * 2013-10-08 2016-06-08 杨波 一种基因工程改造的免疫球蛋白-亲和蛋白
JP6440320B2 (ja) 2013-10-15 2018-12-19 株式会社カネカ 多孔質セルロースビーズの製造方法およびそれを用いた吸着体
JP6517145B2 (ja) 2013-10-15 2019-05-22 株式会社カネカ 多孔質セルロースビーズの製造方法及びそれを用いた吸着体
JP6442409B2 (ja) 2013-10-15 2018-12-19 株式会社カネカ 多孔質セルロースビーズの製造方法
CN104945488B (zh) * 2014-03-27 2020-02-18 迈格生物医药(上海)有限公司 一种具有免疫球蛋白结合能力的多肽
CN105481954B (zh) * 2014-09-16 2021-03-26 亿一生物制药(北京)有限公司 一种重组蛋白a及其应用
JP6369807B2 (ja) * 2014-10-21 2018-08-08 株式会社プロテイン・エクスプレス プロテインl変異体
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10208091B2 (en) 2014-12-17 2019-02-19 Ge Healthcare Bioprocess R&D Ab Modified kappa light chain-binding polypeptides
CN108064286A (zh) 2015-01-26 2018-05-22 株式会社钟化 突变型免疫球蛋白κ链可变区结合性肽
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
JP6805831B2 (ja) 2015-02-05 2020-12-23 三菱ケミカル株式会社 免疫グロブリンに親和性を有するタンパク質、およびそれを用いたアフィニティ分離剤、液体クロマトグラフィー用カラム
CN107429244A (zh) * 2015-03-26 2017-12-01 Jsr株式会社 免疫球蛋白结合蛋白质和使用其的亲和载体
CN106188251B (zh) * 2015-05-06 2020-07-31 上海迈泰君奥生物技术有限公司 一种免疫球蛋白结合蛋白突变体及其用途
JPWO2017014261A1 (ja) * 2015-07-22 2018-04-26 株式会社カネカ 抗体様タンパク質の精製方法
EP3327029A4 (de) * 2015-07-22 2018-10-31 Kaneka Corporation Antikörperbindendes protein mit reduzierter antikörperbindungskapazität in regionen mit saurem ph-wert
GB201515339D0 (en) 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
KR101993845B1 (ko) * 2016-02-18 2019-06-28 (주)에이피테크놀로지 알칼리 저항성이 증대된 항체 친화성 리간드
WO2017191748A1 (ja) * 2016-05-02 2017-11-09 株式会社カネカ 改変型免疫グロブリンκ鎖可変領域結合性ペプチド
WO2017195638A1 (ja) 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
CN109071613A (zh) * 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
CN109311949B (zh) * 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR101857953B1 (ko) * 2016-07-06 2018-05-16 아미코젠주식회사 알칼리 내성이 증가된 변이 면역글로불린 결합 단백질
CN106117324A (zh) * 2016-07-29 2016-11-16 湖北爱晟生物科技有限公司 重组蛋白a及其编码基因和应用
CN109476712B (zh) * 2016-08-11 2022-08-02 纳维格蛋白质有限公司 新型对碱稳定的免疫球蛋白结合蛋白
WO2018048941A2 (en) * 2016-09-08 2018-03-15 The Board Of Trustees Of The Leland Stanford Junior University Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue
CN106543274B (zh) * 2016-10-18 2020-10-27 天津大学 一种对抗体具有特异性结合作用的a蛋白结构域z的衍生物及其应用
BR112019011921A2 (pt) 2016-12-12 2019-11-05 Hurrah S A R L polipeptídeo engenheirado que liga imunoglobulinas ou compostos contendo imunoglobulina, matriz de separação, composição, proteína, meio cromatográfico e método de purificação de uma imunoglobulina
GB201703116D0 (en) 2017-02-27 2017-04-12 Ge Healthcare Bioprocess R&D Ab A seperation matrix and a method of seperating antibodies
GB201708277D0 (en) 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
CN111132994B (zh) 2017-08-07 2024-05-31 瑞普利金公司 在c末端螺旋区中具有半胱氨酸的fc结合蛋白
CN109721645A (zh) * 2017-12-29 2019-05-07 兆生生物科技南京有限公司 一种基因突变的蛋白a及其应用
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
WO2020040307A1 (ja) * 2018-08-24 2020-02-27 Jsr株式会社 イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
JP7117741B2 (ja) * 2018-10-10 2022-08-15 国立大学法人 鹿児島大学 IgG結合性ペプチドを含む固相担体及びIgGの分離方法
CA3123498A1 (en) * 2019-02-01 2020-08-06 Navigo Proteins Gmbh Immunoglobulin binding proteins for affinity purification
WO2020196938A1 (ko) * 2019-03-25 2020-10-01 아미코젠주식회사 불순물 제거능이 우수한 항체 정제용 레진
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
JP2022530852A (ja) * 2019-04-17 2022-07-04 ブリストル-マイヤーズ スクイブ カンパニー クロマトグラフィー樹脂の再生方法
ES2945795T3 (es) 2019-04-29 2023-07-07 Cytiva Bioprocess R & D Ab Método de separación de anticuerpos o fragmentos de anticuerpo que están desprovistos de una región Fc capaz de unirse a la proteína A
CN112210013A (zh) * 2019-07-03 2021-01-12 拜奥普罗塞亚科技有限责任公司 碱耐受性亲和色谱配体
TW202128230A (zh) 2019-10-18 2021-08-01 日商日本醫事物理股份有限公司 具有經ri標定之人類化抗體的複合體、放射性醫藥
CN111057153B (zh) * 2019-12-06 2021-09-07 广州康盛生物科技股份有限公司 一种免疫球蛋白结合蛋白及其制备方法和应用
CN112461943A (zh) * 2020-10-12 2021-03-09 河南省奶牛生产性能测定有限公司 一种牛乳中免疫球蛋白igG高效液相色谱检测方法
JP2023551353A (ja) 2020-10-13 2023-12-08 アヴィタイド エルエルシー 3へリックスバンドルタンパク質の親和性リガンドライブラリー及びその使用
GB202018588D0 (en) 2020-11-26 2021-01-13 Cytiva Bioprocess R & D Ab Separation matrix
WO2022136440A1 (en) 2020-12-21 2022-06-30 Syngenta Crop Protection Ag Pesticidal hexatoxin polypeptides and methods of use thereof
CN117241866A (zh) 2021-02-19 2023-12-15 艾维泰有限责任公司 Aav2亲和剂
JPWO2022225006A1 (de) 2021-04-21 2022-10-27
EP4327833A1 (de) 2021-04-21 2024-02-28 Nihon Medi-Physics Co., Ltd. Radioaktives antitumormittel
GB2609185A (en) 2021-05-24 2023-02-01 Astrea Uk Services Ltd Scaffold for isolation of a biomolecule
GB202109246D0 (en) 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
CN114315996B (zh) * 2021-12-31 2023-01-17 博格隆(浙江)生物技术有限公司 一种重组ProteinA蛋白及亲和层析介质的制备方法
CN114409748A (zh) 2022-01-28 2022-04-29 博格隆(浙江)生物技术有限公司 蛋白a的b结构域和z结构域突变体及其应用
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
CN114605508B (zh) * 2022-05-11 2022-07-29 北京达成生物科技有限公司 能够结合于抗体分子Fc区域的抗体结合蛋白及其应用
CN117700501A (zh) * 2022-09-13 2024-03-15 普米斯生物技术(珠海)有限公司 免疫球蛋白结合蛋白及其应用
CN117024529B (zh) * 2023-07-17 2024-01-26 北京达成生物科技有限公司 抗体结合蛋白及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
DE69230061T2 (de) 1991-07-25 2000-01-05 Oriental Yeast Co. Ltd., Tokio/Tokyo Künstliches immunoglobulin-bindendes protein
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
US7709209B2 (en) * 2002-03-25 2010-05-04 Ge Healthcare Bio-Sciences Ab Protein ligands
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US7993650B2 (en) * 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
US8728828B2 (en) * 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
DK1869071T3 (da) * 2005-03-01 2011-02-28 Affibody Ab TNF-alfa-bindende polypeptid, anvendelser deraf og fremgangsmåder, der gør brug deraf
US20120149875A1 (en) * 2009-01-12 2012-06-14 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
CN103403020A (zh) * 2010-12-21 2013-11-20 Jsr株式会社 蛋白a的新型耐碱变体及其在亲和色谱中的用途
WO2015005859A1 (en) * 2013-07-10 2015-01-15 Ge Healthcare Bio-Sciences Ab Mutated immunoglobulin-binding polypeptides
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) * 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) * 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) * 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method

Also Published As

Publication number Publication date
ES2325362T3 (es) 2009-09-02
EP3249047A2 (de) 2017-11-29
JP4391830B2 (ja) 2009-12-24
ES2325362T5 (es) 2013-02-20
US20210162319A1 (en) 2021-06-03
EP1485407B1 (de) 2009-05-13
KR20120125674A (ko) 2012-11-16
US9296791B2 (en) 2016-03-29
AU2003217119A1 (en) 2003-10-08
KR20040099368A (ko) 2004-11-26
KR20120126129A (ko) 2012-11-20
US20120238724A1 (en) 2012-09-20
KR101307714B1 (ko) 2013-09-11
KR101307651B1 (ko) 2013-09-12
CN102516371A (zh) 2012-06-27
US20110112276A1 (en) 2011-05-12
CN102516372A (zh) 2012-06-27
JP2005538693A (ja) 2005-12-22
KR20110004456A (ko) 2011-01-13
US10918971B2 (en) 2021-02-16
US9156892B2 (en) 2015-10-13
KR101067181B1 (ko) 2011-09-22
ES2634145T3 (es) 2017-09-26
CN102558317A (zh) 2012-07-11
US8354510B2 (en) 2013-01-15
EP1972689B1 (de) 2017-06-07
US20160152668A1 (en) 2016-06-02
EP3249047B1 (de) 2020-02-19
CN102558318A (zh) 2012-07-11
DK1972689T3 (en) 2017-08-14
US9534023B2 (en) 2017-01-03
US8198404B2 (en) 2012-06-12
CN1642976A (zh) 2005-07-20
WO2003080655A1 (en) 2003-10-02
EP1972689A3 (de) 2008-11-19
ES2783876T3 (es) 2020-09-18
EP1485407B2 (de) 2012-09-26
CN1642976B (zh) 2012-02-22
US20060194950A1 (en) 2006-08-31
CN102532284A (zh) 2012-07-04
ATE431360T1 (de) 2009-05-15
US20170080358A1 (en) 2017-03-23
EP1485407A1 (de) 2004-12-15
EP3249047A3 (de) 2018-02-28
CA2479896C (en) 2015-11-17
EP1972689A2 (de) 2008-09-24
DK3249047T3 (en) 2020-03-30
KR101307700B1 (ko) 2013-09-11
CA2479896A1 (en) 2003-10-02
US20130184438A1 (en) 2013-07-18
CN102532284B (zh) 2014-04-16
US20050143566A1 (en) 2005-06-30
US7834158B2 (en) 2010-11-16
AU2003217119B2 (en) 2010-02-18
SE0200943D0 (sv) 2002-03-25
US20100022760A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
ATE431360T1 (de) Mutiertes immunoglobulinbindendes protein
Lund et al. Novel peptide ligand with high binding capacity for antibody purification
DK1562972T3 (da) Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
WO2005123780A3 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
AU2002367839A8 (en) Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
BRPI0409269A (pt) anticorpo modificado da classe igg e método de produção do mesmo
WO2004035170A3 (en) Composition for separating molecules
ATE441715T1 (de) Streptococcus pyogenes antigene
JP2008506960A5 (de)
WO2005037867B1 (en) ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
CN101704879A (zh) 具有改进的特异性的新型免疫球蛋白结合蛋白
WO2004074310A8 (en) Mycobacterial diagnostics
EP2346900A1 (de) Verfahren zur aufreinigung von einzeldomänantigenbindenden molekülen
WO2006130834A3 (en) IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2004067779A3 (en) Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2004081186A3 (en) Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
McCue et al. Validation of the manufacturing process used to produce long‐acting recombinant factor IX Fc fusion protein
RU2010125489A (ru) Способ характеризации рекомбинантного поликлонального белка
ATE428728T1 (de) Verfahren zur reinigung von erythropoietin
JPWO2006001300A1 (ja) 高耐久性液体クロマトグラフィー用充填剤
Yoshida et al. Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site.
EP1960427A4 (de) Multimere fc-rezeptor-polypeptide
WO2004106367A3 (en) Enterococcus antigens
WO2004083403A3 (en) Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2002029094A3 (de) Verfahren zur selektion hochaffin an ein target bindender nukleinsäuren durch zweidimensionale auftrennung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: HAMMONDS LLP, LONDON, GB

R102 Epo decision maintaining patent in amended form now final

Ref document number: 1485407

Country of ref document: EP

Effective date: 20120926

R082 Change of representative

Ref document number: 1485407

Country of ref document: EP

Representative=s name: J D REYNOLDS & CO., GB